Commercial perspective on the drug discovery environment for biopharmaceutical companies in Canada

Drug Development Research

Volumn 42, Issue 3-4, 1997, Pages 113-119

  Bellini, Francesco ^a  

^a Shire Canada   (Canada)

Author keywords

Biotechnology; Genome; Human; Medical research; Patents

Indexed keywords

BIOTECHNOLOGY; CANADA; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; MANAGEMENT; ORGANIZATION; SHORT SURVEY;

EID: 0031393063     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199711/12)42:3/4<113::AID-DDR2>3.0.CO;2-T     Document Type: Short Survey

References (14)

1. Biotechnology Industry Organization (1997). www.bio.org/whatis/ mg3.dgw#b1
2. BioWorld (1997): Biotechnology State of the Industry Report 1997. Atlanta, GA: BioWorld Publishing Group.
3. DiMasi JA (1995): Trends in drug development costs, times and risks. Drug Inf J 29:375-384.
4. Drews J (1997): Strategic choices facing the pharmaceutical industry: A case for innovation. Drug Discov Today 2(2):72-78.
5. Edwards M (1997): Targeting university technology. Signals (an online magazine at www.recap.com/signals.nsf). San Francisco, CA: Recombinant Capital, 1-11.
6. Ernst and Young (1997): Canadian Biotech '97: Coming of Age. Ernst & Young's Fourth Report on the Canadian Biotechnology Industry.
7. Grabowski H, Vernon J (1990): A new look at the returns and risks to pharmaceutical R&D. Manag Sci 36(7):804-821.
8. Hansen RW (1979): The pharmaceutical development process: Estimates of development costs and times and the effects of proposed regulatory changes. In Chien RI (ed): Issues in Pharmaceutical Economics. Lexington, MA: Lexington Books, pp 151-187.
9. Industrial Biotechnology Association of Canada (1997). Ottawa, Ontario, Canada.
10. MacDonald M (1997): Life science sector of growing interest to Canadian venture capitalists. In Ernst and Young: Canadian Biotech 97: Coming of Age. Ernst & Young's Fourth Report on the Canadian Biotechnology Industry.
11. Patented Medicine Prices Review Board (PMPRB) (1997): Newsletter, vol. 1, no. 1, July. Ottawa, Ontario, Canada.
12. Pharmaceutical Manufacturers Association of Canada (1997): 1997-1998 Annual Review: Medicines and the New Millennium. Ottawa, Ontario, Canada.
13. U.S. Congress, Office of Technology Assessment (1993): Pharmaceutical R&D: Costs, Risks and Rewards, OTA-H-522. Washington, DC: U.S. Government Printing Office, February.
14. U.S. National Institutes of Health (1996): 1997 budget boosts NIH, medical research overall. NIH Record (October 22) (www.nih.gov/ news/NIH-Record/10_22_96/story01.htm).